Isomerase Therapeutics

Isomerase Therapeutics is a private, Cambridge-based synthetic biology CRO/platform company specializing in microbial engineering for therapeutic and industrial applications. Its core offering is the IsoZym® Bioproduction Platform, which integrates enzyme discovery, machine learning-guided optimization, strain engineering, and process development to enable partners to produce complex molecules. The company appears to be in an early-revenue stage, generating income through FTE-based service packages and collaborative R&D, rather than advancing a proprietary therapeutic pipeline. Its business model focuses on partnering with biopharma and industrial companies to accelerate their discovery and bioproduction efforts.

IsoZym® Bioproduction Platform: An integrated suite for enzyme discovery (via bioinformatics & ML), microbial strain engineering, cell-free protein synthesis, and bioprocess development to produce enzymes, proteins, peptides, and natural products.

Isomerase competes with other synthetic biology and enzyme engineering CROs (e.g., Ginkgo Bioworks via its platform services, smaller specialized firms) and the internal R&D capabilities of large pharma/industrial biotech companies. Its differentiation lies in its specific focus on microbial systems for complex natural products and its integrated end-to-end service model.